{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"description":"CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever greater than 38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes \\>20%.\n\nAML, ALL \\>5% marrow blasts by morphologic or flow cytometric, or appearance of extramedullary disease.\n\nCLL ≥1 of: Physical exam/Imaging studies (nodes, liver, and/or spleen) ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.\n\nNHL \\>25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.\n\nMM\n\n≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions.","groups":[{"description":"CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total-body irradiation on day -1.\n\nDONOR BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0.\n\nPOST-TRANSPLANTATION IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3 and mycophenolate mofetil PO TID on days 4 - 40, followed by a taper until day 84 in the absence of GVHD. Patients also receive tacrolimus IV continuously or IV QD over 1-2 hours or PO BID on days 4 - 84, followed by a taper until day 180 in the absence of GVHD.\n\nNK CELL INFUSION: Patients undergo donor lymphocyte infusion of 2.5 x 10\\^6/kg NK cells on day 7.\n\nAllogeneic Bone Marrow Transplantation: Undergo donor bone marrow transplantation\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Dose 1 (2.5 x 10^6/kg NK Cells)"},{"description":"CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total-body irradiation on day -1.\n\nDONOR BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0.\n\nPOST-TRANSPLANTATION IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3 and mycophenolate mofetil PO TID on days 4 - 40, followed by a taper until day 84 in the absence of GVHD. Patients also receive tacrolimus IV continuously or IV QD over 1-2 hours or PO BID on days 4 - 84, followed by a taper until day 180 in the absence of GVHD.\n\nNK CELL INFUSION: Patients undergo donor lymphocyte infusion of 5.0 x 10\\^6/kg NK cells on day 7.\n\nAllogeneic Bone Marrow Transplantation: Undergo donor bone marrow transplantation\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG001","title":"Dose 2 (5.0 x 10^6/kg NK Cells)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One subject aborted transplant after conditioning due to donor ineligibility. This subject was counted towards accrual but not evaluated with respect to outcome measures.","reportingStatus":"POSTED","timeFrame":"At 1 year","title":"Number of Participants With Relapsed Disease","type":"PRIMARY","unitOfMeasure":"Participants"}